Acetylon Pharmaceuticals, Inc., the leader in the development of selective histone deacetylase (HDAC) inhibitors for enhanced therapeutic outcomes, today announced that its selective HDAC inhibitor drug candidates will be the subject of eleven presentations, including three oral presentations and eight poster presentations of preclinical and clinical research in multiple myeloma, lymphoma and sickle cell disease/ß-thalassemia at the American Society of Hematology (ASH) Annual Meeting to be held December 7-10, 2013, in New Orleans, LA.
Help employers find you! Check out all the jobs and post your resume.
